Aigen Investment Management LP Makes New $479,000 Investment in Haemonetics Co. (NYSE:HAE)

Aigen Investment Management LP acquired a new position in Haemonetics Co. (NYSE:HAE) in the third quarter, Holdings Channel.com reports. The fund acquired 5,959 shares of the medical instruments supplier’s stock, valued at approximately $479,000.

Other hedge funds also recently added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Haemonetics during the second quarter valued at about $39,000. Covestor Ltd grew its stake in Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 438 shares during the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Haemonetics in the second quarter valued at about $82,000. Canada Pension Plan Investment Board purchased a new position in shares of Haemonetics in the second quarter worth about $83,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Haemonetics during the first quarter worth about $86,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on HAE shares. Bank of America initiated coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price on the stock. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective for the company in a research note on Friday, November 8th. Citigroup lowered their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Barrington Research restated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a report on Friday, November 8th. Finally, CL King began coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 target price for the company. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Price Performance

Haemonetics stock opened at $90.75 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The stock has a market cap of $4.56 billion, a P/E ratio of 38.08, a PEG ratio of 1.45 and a beta of 0.32. The company has a 50-day moving average price of $76.90 and a 200 day moving average price of $82.71. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 EPS. Sell-side analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.